Early Access — free while we kick the tires
EdgarHawk

Venkatachaliah Girish

Chief Technology Officer

Officer
2 filings analyzed · 1 company · Latest 2026-03-11

Companies

Company Buys Sells Direction
agilon health, inc. AGL 4 0 Net buying

Activity

March 2026
2026-03-11 agilon health, inc. AGL
medium
Buy
18,448 shares
Significance 5/10

CTO Venkatachaliah Girish bought 18,448 shares of AGL; stock down -88.8% from 52-week high despite cluster buy activity.

Venkatachaliah Girish, Chief Technology Officer, purchased 18,448 shares on 2026-03-09, increasing his holdings by 7.1% to 278,607 shares total. The transaction occurs within a 14-day cluster pattern where 2 other insiders also bought, which may indicate coordinated confidence at depressed valuations. However, context tempers this signal: the current price of $15.94 is -88.8% from the 52-week high of $142.00, and the company remains unprofitable with net income of $-110,207,000 for the latest quarter and annual revenue growth of -2.1%. In his prior two purchases at this ticker, the CTO's timing has been mixed—one achieved a 90-day gain of +31.6% while the other declined -45.9% over the same period—offering no clear pattern of prescient buying.

March 2025
2025-03-18 agilon health, inc. AGL
high
Buy
9,429 shares
Significance 7/10

CTO Girish buys 9,429 AGL shares; cluster activity as 2 other insiders bought in past 14 days

Venkatachaliah Girish, Chief Technology Officer, purchased 9,429 shares on 2025-03-14, increasing his holdings by 6.5% to 155,120 shares. This buy occurs within a broader insider buying cluster—2 other insiders also acquired shares within the past 14 days—signaling coordinated confidence at the executive level. The timing is notable: Girish's prior buy at AGL on 2024-03-14 delivered +31.6% 90-day return, establishing a pattern of well-timed entry points at this ticker. The company's fundamentals present a mixed picture: annual revenue growth of +40.4% demonstrates strong top-line expansion, but a net loss of $-117,615,000.00 over the most recent full fiscal year underscores profitability challenges despite $1,450,932,000.00 in quarterly revenue. The stock has surged +121.5% over 90 days yet remains -42.6% from its 52-week high of $188.00, leaving open questions about whether insiders are accumulating at an attractive entry point or chasing momentum in a loss-making, high-growth business.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access